Amgen has boosted its portfolio of cancer-targeted bispecific antibodies with the purchase of Teneobio for $900 million—plus as much as $1.6 billion more for meeting certain developmental milestones. The acquisition includes a potential treatment for prostate cancer and several other products.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.